MoonLake Immunotherapeutics MLTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's stock-based comp?
- MoonLake Immunotherapeutics (MLTX) reported stock-based comp of $13.36M in Q1 2026.
- How has MoonLake Immunotherapeutics's stock-based comp changed year-over-year?
- MoonLake Immunotherapeutics's stock-based comp increased by 483.2% year-over-year, from $2.29M to $13.36M.
- What is the long-term trend for MoonLake Immunotherapeutics's stock-based comp?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's stock-based comp has grown at a 10.1% compound annual growth rate (CAGR), from $9.65M to $12.9M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.